Home›Research›Compare›Angiotensin (1-7) vs Foxo4-DRI
Peptide ComparisonAngiotensin (1-7) vs Foxo4-DRI
Both are Longevity & Cellular peptides.
Angiotensin (1-7)
Ang-(1-7)
Half-life: ~9–10 sec (rat)
No providers listed yet
Foxo4-DRI
Foxo4-D-Retro-Inverso
Half-life: Unknown
13 providers listed
Angiotensin (1-7) carries stronger published evidence (RCT, 15 key studies) than Foxo4-DRI (Review, 3); both are research compounds.
Angiotensin (1-7)
Evidence
Half-life
~9–10 sec (rat)
Foxo4-DRI
Evidence
Half-life
Unknown
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Angiotensin (1-7) |
| Further along in FDA review | Angiotensin (1-7) |
| More provider options (0 vs 13) | Foxo4-DRI |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Angiotensin (1-7)
Foxo4-DRI
Angiotensin (1-7)
The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.
Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…
+11 more
Foxo4-DRI
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigat…
Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-…
About Angiotensin (1-7)
Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.
About Foxo4-DRI
D-retro-inverso peptide that disrupts Foxo4/p53 interaction in senescent cells; restores p53-mediated apoptosis selectively in senescent cells; clears cellular "zombie cells"
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Angiotensin (1-7)
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Foxo4-DRI
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Angiotensin (1-7)
Not enough vendor pricing yet.
Foxo4-DRI
Where to source these peptides
Angiotensin (1-7)
Browse directory →
Providers offeringFoxo4-DRI
13 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Angiotensin (1-7) vs Foxo4-DRI — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/foxo4-dri